FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039725572> ?p ?o ?g. }

• W2039725572 endingPage "603" @default.
• W2039725572 startingPage "595" @default.
• W2039725572 abstract "This multicentre, single arm, phase II study was aimed to assess the efficacy and safety of pazopanib as second-line treatment after failure of sunitinib in patients with metastatic renal cell carcinoma (mRCC) and explore biomarkers for pazopanib response. Patients received pazopanib 800mgperday. The primary end-point was progression-free survival (PFS). Secondary end-points included objective response rate (ORR), overall survival (OS) and safety. Serum proteins (Delta-like ligand (DLL4), Notch1, hypoxia inducible factor-1α (HIF-1α), HIF-2α, vascular endothelial growth factor A (VEGFA) and platelet-derived growth factor receptor β (PDGFRB)) levels were measured using enzyme-linked immunosorbent assay (ELISA). 86 patients with clear cell mRCC were enrolled from December 2009 to March 2012 from three centres in Southern China. Of 85 evaluable patients, the median PFS was 5.6months (95% confidence interval (CI), 4.1-6.7months) by independent review. No complete response (CR) was observed in all patients. 13 (15.3%; 95% confidence interval [CI], 11.2-23.9%) patients achieved partial responses (PR) (ORR 15.3%). Median OS was 18.1months (95% CI, 13.2-19.8months). The most common adverse events (AEs) were mild to moderate and clinically manageable, including hypertension (37.6%), diarrhoea (36.5%), increased AST (51.8%), and anaemia (60%). AEs resulted in dose reduction in 24.7% of patients. Multivariable analysis showed that higher baseline levels of DLL4 and VEGFA and lower baseline level of HIF-2α were associated with shorter PFS; only lower baseline level of HIF-2α was correlated with shorter OS. The lower expression level of DLL4 after pazopanib treatment was associated with higher response rate probability. In conclusion, pazopanib was clinically active and well tolerated as second-line treatment after sunitinib in mRCC patients. Baseline levels of serum DLL4, VEGFA and HIF-2α may have potential utility as biomarkers of clinical efficacy in this setting (chiCTR-TRC-13004016)." @default.
• W2039725572 created "2016-06-24" @default.
• W2039725572 creator A5025301183 @default.
• W2039725572 creator A5028486410 @default.
• W2039725572 creator A5031643585 @default.
• W2039725572 creator A5088063713 @default.
• W2039725572 date "2015-03-01" @default.
• W2039725572 modified "2023-09-29" @default.
• W2039725572 title "Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: A Southern China Urology Cancer Consortium Trial" @default.
• W2039725572 cites W1544119899 @default.
• W2039725572 cites W1967193000 @default.
• W2039725572 cites W1972160639 @default.
• W2039725572 cites W1978083619 @default.
• W2039725572 cites W1982245010 @default.
• W2039725572 cites W1982765892 @default.
• W2039725572 cites W1992814996 @default.
• W2039725572 cites W2023952988 @default.
• W2039725572 cites W2035510806 @default.
• W2039725572 cites W2035900169 @default.
• W2039725572 cites W2039035303 @default.
• W2039725572 cites W2056296460 @default.
• W2039725572 cites W2068675926 @default.
• W2039725572 cites W2073400280 @default.
• W2039725572 cites W2075281345 @default.
• W2039725572 cites W2076911447 @default.
• W2039725572 cites W2081505922 @default.
• W2039725572 cites W2081704237 @default.
• W2039725572 cites W2098041761 @default.
• W2039725572 cites W2099088585 @default.
• W2039725572 cites W2099208826 @default.
• W2039725572 cites W2109666777 @default.
• W2039725572 cites W2115822788 @default.
• W2039725572 cites W2117748018 @default.
• W2039725572 cites W2118677643 @default.
• W2039725572 cites W2122538070 @default.
• W2039725572 cites W2124396025 @default.
• W2039725572 cites W2129925362 @default.
• W2039725572 cites W2135400147 @default.
• W2039725572 cites W2136110110 @default.
• W2039725572 cites W2136434660 @default.
• W2039725572 cites W2141444851 @default.
• W2039725572 cites W2142980017 @default.
• W2039725572 cites W2147535764 @default.
• W2039725572 cites W2153726848 @default.
• W2039725572 cites W2162424705 @default.
• W2039725572 cites W2170417775 @default.
• W2039725572 cites W2277659015 @default.
• W2039725572 doi "https://doi.org/10.1016/j.ejca.2015.01.005" @default.
• W2039725572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25618828" @default.
• W2039725572 hasPublicationYear "2015" @default.
• W2039725572 type Work @default.
• W2039725572 sameAs 2039725572 @default.
• W2039725572 citedByCount "14" @default.
• W2039725572 countsByYear W20397255722015 @default.
• W2039725572 countsByYear W20397255722016 @default.
• W2039725572 countsByYear W20397255722017 @default.
• W2039725572 countsByYear W20397255722018 @default.
• W2039725572 countsByYear W20397255722019 @default.
• W2039725572 countsByYear W20397255722021 @default.
• W2039725572 countsByYear W20397255722022 @default.
• W2039725572 crossrefType "journal-article" @default.
• W2039725572 hasAuthorship W2039725572A5025301183 @default.
• W2039725572 hasAuthorship W2039725572A5028486410 @default.
• W2039725572 hasAuthorship W2039725572A5031643585 @default.
• W2039725572 hasAuthorship W2039725572A5088063713 @default.
• W2039725572 hasConcept C126322002 @default.
• W2039725572 hasConcept C126894567 @default.
• W2039725572 hasConcept C143998085 @default.
• W2039725572 hasConcept C197934379 @default.
• W2039725572 hasConcept C203092338 @default.
• W2039725572 hasConcept C2776694085 @default.
• W2039725572 hasConcept C2777472916 @default.
• W2039725572 hasConcept C2777802072 @default.
• W2039725572 hasConcept C2778439243 @default.
• W2039725572 hasConcept C2779490328 @default.
• W2039725572 hasConcept C2779984678 @default.
• W2039725572 hasConcept C2781278892 @default.
• W2039725572 hasConcept C31760486 @default.
• W2039725572 hasConcept C535046627 @default.
• W2039725572 hasConcept C71924100 @default.
• W2039725572 hasConcept C90924648 @default.
• W2039725572 hasConceptScore W2039725572C126322002 @default.
• W2039725572 hasConceptScore W2039725572C126894567 @default.
• W2039725572 hasConceptScore W2039725572C143998085 @default.
• W2039725572 hasConceptScore W2039725572C197934379 @default.
• W2039725572 hasConceptScore W2039725572C203092338 @default.
• W2039725572 hasConceptScore W2039725572C2776694085 @default.
• W2039725572 hasConceptScore W2039725572C2777472916 @default.
• W2039725572 hasConceptScore W2039725572C2777802072 @default.
• W2039725572 hasConceptScore W2039725572C2778439243 @default.
• W2039725572 hasConceptScore W2039725572C2779490328 @default.
• W2039725572 hasConceptScore W2039725572C2779984678 @default.
• W2039725572 hasConceptScore W2039725572C2781278892 @default.
• W2039725572 hasConceptScore W2039725572C31760486 @default.
• W2039725572 hasConceptScore W2039725572C535046627 @default.
• W2039725572 hasConceptScore W2039725572C71924100 @default.
• W2039725572 hasConceptScore W2039725572C90924648 @default.
• W2039725572 hasFunder F4320321001 @default.

• next